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Abstract
Background: MicroRNAs (miRNAs) play an important role in the regulation of cell growth, differentiation,
apoptosis, and carcinogenesis. Detection of their expression may lead to identifying novel markers for breast
cancer.
Methods: We profiled miRNA expression in three breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-MB-468)
and then focused on one miRNA, miR-339-5p, for its role in regulation of tumor cell growth, migration, and
invasion and target gene expression. We then analyzed miR-339-5p expression in benign and cancerous breast
tissue specimens.
Results: A number of miRNAs were differentially expressed in these cancer cell lines. Real-time PCR indicated that
miR-339-5p expression was downregulated in the aggressive cell lines MDA-MB-468 and MDA-MB-231 and in
breast cancer tissues compared with benign tissues. Transfection of miR-339-5p oligonucleotides reduced cancer
cell growth only slightly but significantly decreased tumor cell migration and invasion capacity compared with
controls. Real-time PCR analysis showed that BCL-6, a potential target gene of miR-339-5p, was downregulated in
MDA-MB-231 cells by miR-339-5p transfection. Furthermore, the reduced miR-339-5p expression was associated
with an increase in metastasis to lymph nodes and with high clinical stages. Kaplan-Meier analyses found that the
patients with miR-339-5p expression had better overall and relapse-free survivals compared with those without
miR-339-5p expression. Cox proportional hazards analyses showed that miR-339-5p expression was an independent
prognostic factor for breast cancer patients.
Conclusions: MiR-339-5p may play an important role in breast cancer progression, suggesting that miR-339-5p
should be further evaluated as a biomarker for predicting the survival of breast cancer patients.
Background
Breast cancer is accounted approximately 26% of new
cases of all cancers in women in 2009 and is the third
most common cause of cancer death in the Unite States
[1]. Breast cancer, like other cancers, occurs through
multiple genetic alterations, such as activation of onco-
genes or inactivation of tumor-suppressor genes.
Although improved screening techniques now help
detect breast cancer at early stages and advanced
treatment remarkably improves patient survival, tumor
invasion and metastasis still contribute to the great
majority of breast cancer deaths. Our efforts towards
the diminution of the disease should include developing
novel biomarkers for early detection, prediction of treat-
ment response, monitoring disease progression, and
prognosis as well as novel approaches for the treatment
and prevention of breast cancer. Although currently
there are various techniques for screening breast cancer,
such as clinical and self breast examinations, mammo-
graphy, genetic screening, ultrasound, and magnetic
resonance imaging, useful genetic screening biomarkers * Correspondence: aydjohn@yahoo.com
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needed.
MicroRNAs (miRNAs), a class of non-protein-coding
RNAs, can postranscriptionally silence protein expres-
sion either by binding to complementary target messen-
ger RNAs, thereby degrading these messenger RNAs, or
by inhibiting them from translating into proteins [2-4].
Recent studies have demonstrated that miRNAs are use-
ful attractive candidates for biomarkers for the early
detection and prognosis of breast cancer. For example,
miR-21, miR-10b, and miR-335 have been shown to be
involved in the formation and progression of breast can-
cer by targeting certain oncogenes or tumor suppressors
[5-7]. Most importantly, a number of studies have found
that miRNAs play an important role in the regulation of
cell growth, differentiation, apoptosis, and carcinogen-
esis [8-13].
In this study, we first determined the expression pro-
file of miRNAs using miRNA arrays in different breast
cancer cells with diverse invasive ability and then chose
one of them, miR-339-5p, for further study of its expres-
sion in breast cancer tissue specimens using in situ
hybridization. We then explored its role in breast cancer
cell growth and invasion capacity as well as its potential
for targeting genes. Our goal was to determine whether
detection of miRNA expression might be a useful prog-
nostic biomarker in patients with breast cancer.
Methods
Cell lines and cultures
The human breast cancer cell lines MCF-7, MDA-MB-
231, and MDA-MB-468 were obtained from the Ameri-
can Type Culture Collection (Rockville, MD). MCF-7
cells were grown in RPMI 1640 medium and MDA-MB-
231 and MDA-MB-468 in Leibovitz’sL - 1 5c e l lc u l t u r e
medium with 10% fetal bovine serum at 37°C in a humi-
dified atmosphere of 95% air and 5% CO2.
RNA isolation and miRNA microarray analysis
Total RNA from the breast cancer cell lines or fresh tis-
sue samples was extracted using the mirVANA RNA
isolation kit (Ambion, Austin, TX) according to the
manufacturer’s instructions. After the RNA samples
were quantified on a NanoDrop spectrophotometer
(Nanodrop, Wilmington, DE), they were stored in ali-
quots at -80°C until use. For microarray analysis, the
RNA samples were first labeled with fluorescence dye
hy3 or hy5 using a miRCURY Hy3/Hy5 power labeling
kit and then hybridized onto the miRCURY LNA array
(both obtained from Exiqon, Copenhagen, Denmark).
This miRNA array contained 847 human miRNA
sequences based on Sanger miRBase release 11.0. The
microarray was scanned using the Axon GenePix 4000B
microarray scanner and analyzed using GenePix pro
V 6 . 0 ,a n dt h ed a t aw e r et h e nn o r m a l i z e db yt h el o c a l l y
weighted scatter plot smoothing (LOWESS) method
based on the background-subtracted data. All these pro-
cedures were performed by Exiqon.
Real-time polymerase chain reaction
RNA samples from breast cancer cell lines or tissue sam-
ples were subjected to reverse transcription reactions in a
mixture of dNTP, a RevertAid MMuLV reverse transcrip-
tase, and RiboLock ribonuclease inhibitor (Applied Biosys-
tems, Foster City, CA). Next, the cDNA was amplified by
real-time PCR (ABI PRISM 7300 Sequence Detection Sys-
tem, Applied Biosystems) in an SYBR Green I Real-Time
PCR kit (GenePharma, Shanghai, China) for expression of
miR-339-5p. U6 small nuclear RNA was used as an inter-
nal control. The following primers were used: miR-339-5p,
5’-GTCGTATCCAGTGCGTGTCGTGGAGTCGGCA
ATTGCACTGGATACGACCGTGAGCTC-3’ (a stem-
loop primer); 5’-GGGTCCCTGTCCTCCA-3’ (forward);
5’-TGCGTGTCGTGGAGTC-3’ (reverse) and U6,
5’-GCTTCGGCAGCACATATACTAAAAT-3’ (forward);
5’-CGCTTCACGAATTTGCGTGTCAT-3’ (reverse). The
PCR amplification protocol was as follows: an initial 95°C
for 5 min and 50 cycles of 94°C for 15 s, 55°C for 30 s, and
70°C for 30 s. The threshold cycle (Ct) was defined as the
fractional cycle number at which the fluorescence passes
the fixed threshold. The relative quantification of miRNA
expression in each sample was calculated with the 2
- ΔΔ Ct
method after normalization for expression of the positive
control. Along with the reverse transcription and real-time
PCR, a negative control without Taq enzyme or cDNA
template was used to exclude PCR contamination and
genomic DNA.
To quantify expression of B-cell lymphoma gene 6
(BCL-6) mRNA, we used the SYBR Premix Ex Taq
(Perfect Real Time) kit (TaKaRa, Dalian, China) to
detect BCL-6 mRNA levels with the ABI PRISM 7300
sequence detector. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA was used as an internal
control. The following primers were used: for BCL-6,
5’-CCAGCCACAAGACCGTCCAT-3’ (forward) and
5’-CTCCGCAGGTTTCGCATTT-3’ (reverse); and for
GAPDH, 5’-TGCACCACCAACTGCTTAGC-3’ (for-
ward) and 5’-GGCATGGACTGTGGTCATGAG-3’
(reverse).
Transient miRNA transfection
Breast cancer MDA-MB-231 and MCF-7 cells (1.0 × 10
6
per well) were seeded and grown overnight in six-well
plates. The next day, they were transfected with either
miR-339-5p mimic (GenePharma, Shanghai, China), 2’-O
methylated single-stranded miR-339-5p antisense oligonu-
cleotides (ASO) (GenePharma, Shanghai, China), or
the control oligonucleotides using Lipofectamine 2000
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instructions. The miRNA mimics are small double-
stranded RNA oligonucleotides. The negative control
RNA (GenePharma) was used to eliminate the potential
nonsequence-specific effects, and the sequences were non-
homologous to any human genome sequences. The
sequences of miR-339-5p mimic and ASO were 5’-UCC-
CUGUCCUCCAGGAGCUCACG UGAGCUCCUGGAG-
GACAGGGAUU-3’ and 5’-CGUGAGCUCCUGGAGG
ACAGGGA-3’, respectively. Nonspecific sequences were
5’-CAGUACUUUUGUGUAGUACAA-3’ (a negative con-
trol for miRNA mimic), 5’-UUCUCCGAACGUGUCAC-
GUTT-3’ (sense), and 5’-ACGUGACACGUUCGUA
GAATT-3’ (antisense), a negative control for mRNA anti-
sense transfection. Transfection efficiency was confirmed
by real-time PCR analysis of miR-339-5p levels in the
transfected breast cancer cells.
Cell viability assay
MCF-7 cells (5 × 10
3) were suspended in RPMI 1640
medium (100 μl) containing 10% fetal bovine serum and
cultured in 96-well plates overnight and then transfected
with miR-339-5p ASO or negative control oligonucleo-
tides for 48, 72, and 96 h, respectively. The cell viability
was determined by using a WST-8 cell counting Kit-8
(Beyotime, Jiangsu, China). Briefly, CCK-8 solution
(10 μl) from the kit was added to each well of the 96-
well plates, the plates were incubated at 37°C in a CO2
cell incubator for 90 min, and the absorbance rates were
measured at 450 nm using a microplate reader (Infinite
M200; Tecan, Austria). All experiments were performed
in triplicate and repeated trice. The data were plotted as
means ± SD of three separate experiments.
Wound-healing assay
An in vitro wound healing/scratch assay was used to assess
capacity for tumor cell motility. Briefly, MCF-7 cells (1 ×
10
6/well) were seeded in six-well plates, cultured over-
night, and transfected with miR-339-5p ASO and the
negative control. Upon reaching confluency, the cell layer
was scratched with a sterile plastic tip and then immedi-
ately washed with growth medium twice and cultured
again in RPMI 1640 medium (including 10% FBS) at 37°C
in a humidified incubator with 5% CO2 for up to 72 h. At
different time points, photo images of the plates were
taken under a microscope. The wound healing was mea-
sured at 0, 24, 48, and 72 h, and the data were summarized
based on sextuple assays for each experiment.
Cell migration and invasion assay
We used a Transwell insert (24-well insert, pore size 8
μm; Corning, Inc., Corning, NY) to determine the effect
of miR-339-5p on breast cancer cell migration and inva-
sion in vitro. Briefly, the transfected MDA-MB-231 and
MCF-7 cells were first starved in medium without fetal
calf serum (FCS) overnight, and the cells (5 × 10
5 for
MDA-MB-231 and 1 × 10
6 for MCF-7) were resus-
pended in the FCS-free medium and placed in the top
chambers in triplicate. The lower chamber was filled
with 10% FCS as the chemoattractant and incubated for
36 h (for MDA-MB-231) or 48 h (for MCF-7) for the
invasion assay. For the invasion assay, the inserts were
previously coated with extracellular matrix gel from
Engelbreth-Holm-Swarm mouse sarcoma (BD Bios-
ciences, Bedford, MA). At the end of the experiments,
the cells on the upper surface of the membrane were
removed using cotton buds, and the cells on the lower
surface of the insert were fixed and stained with 0.1%
crystal violet. Five visual fields of each insert were ran-
domly chosen and photographed under a light micro-
scope at 200 × magnification. The cells in the
photographs were counted, and the data were summar-
ized as means ± standard deviation and presented as a
percentage of controls.
Breast tissue specimens
Ninety consecutive surgical breast tissue specimens from
patients with breast cancer and 26 from patients with
benign breast disease were obtained from the First
Affiliated Hospital of Anhui Medical University (Hefei,
Anhui, China) between November 2001 and June 2002.
Patients who had received any chemotherapy or radia-
tion therapy before surgery or who had rheumatic dis-
ease, acute infection, HIV, or other types of cancer were
excluded from the current study. The pathohistological
diagnosis of the specimens was consistent with breast
neoplasm in accordance with WHO guidelines [14]. His-
tologic grade was based on the Scarff-Bloom-Richardson
system [15]. All breast cancer patients were female and
had undergone radical mastectomy or modified radical
mastectomy. Of the 90 patients, 86 had full follow-up
data. The median follow-up time was 60 months (range
8-64 months).
The protocol for the use of tissue samples from
patients and follow-up study was approved by our Insti-
tutional Review Board, and every patient had signed a
consent form. Our study procedures were in accordance
with the ethical standards of the responsible committee
on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2008.
Tissue microarray construction
Formalin-fixed and paraffin-embedded tissue blocks of the
patients’ tissues were retrieved from the Department of
Pathology, the First Affiliated Hospital of Anhui Medical
University, Hefei, China. Hematoxylin and eosin-stained
tissue sections were then reviewed to identify representa-
tive tissues for tissue microarray (TMA). Three to five
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embedded blocks for each patient for assembling the
TMA blocks by using a manual tissue arrayer (Hengtai
Instruments Inc., Liaoning, China). A total of three TMA
blocks were prepared and sectioned for in situ hybridiza-
tion analysis of miRNA expression.
In situ hybridization
The assay was performed as described previously [16-18]
for analysis of miR-339-5p expression in breast tissue spe-
cimens. Briefly, 3-μm-thick TMA sections were deparaffi-
nized, rehydrated, and then digested with protease and
refixed in 4% paraformaldehyde. After that, the sections
were prehybridized with 150 μl of hybridization solution
and incubated with LNA-modified probes (Exiqon,
Copenhagen, Denmark) for miR-339-5p, U6 (a positive
control), or scrambled RNA (a negative control) at 60°C
for 20 h. After the sections were washed with 2 × SSC,
and then 1 × SCC, they were incubated with a mouse
biotinylated anti-digoxigenin antibody followed by incuba-
tion with a streptavidin-biotin-peroxidase complex solu-
tion. For color reaction, the sections were incubated with
a 3,3’-diaminobenzidine solution and counterstained with
hematoxylin. The stained sections were reviewed and
scored under a light microscope (Olympus America,
Melville, NY) independently by two investigators. The
staining intensity and percentage of tissue staining were
recorded. If less than 10% of the cells stained weakly posi-
tive, the core tissue was scored as negative. If more than
10% of the cells stained positive, this core was scored as
positive [18]. If any of the three to five cores per case
stained positive, that case was considered to be positive
Bioinformatic and statistical analysis
We searched three miRNA databases (miRbase [19],
TargetScan [20], and Pic Tar [21]) for prediction of
miR-339-5p targets. All statistical analyses were per-
formed using SPSS software for Windows (version 13.0;
SPSS, Chicago, IL). Differences between two groups
were compared using Pearson’s chi-square test for quali-
tative variables and Student’s t-test for continuous vari-
ables. Kaplan-Meier curves were constructed to
determine patient relapse-free survival and overall survi-
val rates. The statistical differences in survival among
subgroups were compared using the log-rank test.
A multivariate Cox proportional hazards regression ana-
lysis was used to confirm predictors of case fatality.
P values < 0.05 were considered statistically significant.
Results
Expression of miR-339-5p in breast cancer cells and tissue
samples
To explore the differential expression of miRNAs in
breast cancer cells with different potentials for invasion
and metastasis, we performed the miRCURY LNA array
analysis in three breast cancer cell lines, MCF-7, MDA-
MB-468, and MDA-MB-231 cells. The data were ana-
lyzed according to the tumor cell behavior: for example,
Group 1 contained low-invasive MCF-7 cells, and
Group 2 included relatively highly invasive MDA-MB-
231 and MDA-MB-468 cells. The standard of statistical
significance was the corrected ratio of hybridization
signal intensity between Group 1 (MCF-7 cells) and
Group 2 (MDA-MB-231 or MDA-MB-468 cells). If their
ratios were equal or more than 2.0 or less than 0.5,
expression of miRNAs was considered significantly dif-
ferent. Of the 847 human miRNAs on the array, 98
showed significant differences between Group 1 and
Group 2 tumor cells (Additional file 2, Table S1). In
particular, 46 mRNAs were upregulated and 52 miRNAs
were downregulated (Additional file 1, Fig. S1) in Group
2 cells compared with Group 1 cells, based on hierarchi-
cal clustering analysis. We then chose miR-339-5p for
further study because its expression was reduced more
than fivefold and tenfold in MDA-MB-231 and MDA-
MB-468 cells, respectively, compared with MCF-7 cells
in the miRNA microarray analysis. Real-time PCR analy-
sis confirmed that miR-339-5p was significantly lower in
the MDA-MB-231 and MDA-MB-468 cells than in
MCF-7 cells (P < 0.001, Fig. 1A).
Next, we used breast tissue specimens to further verify
the array data on cell lines. We performed real-time
PCR analysis of miR-339-5p expression in fresh tissues
from 12 breast cancer patients with lymph node metas-
tasis, 13 breast cancer patients without lymph node
metastasis, and nine patients with benign breast disease.
We found that levels of miR-339-5p expression in breast
cancer with lymph node metastasis were significantly
lower than levels for breast cancer without lymph node
metastasis or for benign disease (P < 0.01, Fig. 1B).
Effects of miR-339-5p on breast cancer cell growth
To determine the effects of miR-339-5p in breast cancer
cells, we first performed transient miRNA transfection
and cell viability assays to detect its ability to regulate
tumor cell viability in MCF-7 and MDA-MB-231 cells.
We found that knockdown of miR-339-5p expression in
MCF-7 cells using miR-339-5p ASO did not significantly
reduce the cell viability (Fig. 2A), and expression of
miR-339-5p in MDA-MB-231 cells using miR-339-5p
mimic oligonucleotides also did not induce tumor cell
growth (data not shown).
Effects of miR-339-5p on breast cancer cell migration and
invasion
We next assayed whether miR-339-5p can change the
capacity of breast cancer cells for migration and inva-
sion. MDA-MB-231 and MCF-7 cells were selected for
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ent gene transfection. As shown in Fig. 2B, tumor cells
with miR-339-5p knockdown rapidly closed the scratch
wounds compared with the control cells (P < 0.001).
Moreover, the cell migration and invasion assay showed
that miR-339-5p knockdown resulted in increased MCF-
7 cell migration rate (7.60 ± 2.28-fold, P <0 . 0 0 1 )a n d
invasion rate (5.93 ± 2.23-fold, P <0 . 0 0 1 )c o m p a r e d
with the control cells (Fig. 2C). In contrast, ectopic
expression of miR-339-5p in MDA-MB-231 cells
resulted in significant reduction of cell migration and
invasion in transwell assays (P < 0.001) (data not
shown).
BCL-6, a putative target of miR-339-5p
Bioinformatic analyses found that the BCL-6 gene,
among a number of others, may be a potential miR-339-
5p target. We chose BCL-6 for further analysis because
it was predicted by all three algorithms and was also
previously implicated in promoting breast cancer pro-
gression [22-24]. Indeed, we found that MCF-7 cells
transfected with miR-339-5p ASO or MDA-MB-231
cells transfected with miR-339-5p mimics had dramati-
cally increased or lowered BCL-6 levels by 5 fold and 10
fold, respectively, compared with the control cells (both
P < 0.001, Fig. 3).
Expression of miR-339-5p in breast tissue specimens and
the clinicopathologic features of the patients
Next, we utilized digoxigenin-labeled locked nucleic
acid (LNA)-miRNA probes to detect miR-339-5p levels
in archived breast tissue specimens. A scrambled
oligonucleotide was used to demonstrate specificity of
hybridization. A total of 90 paraffin-embedded tissue
specimens of breast cancer, 24 adjacent normal breast
and 26 benign breast disease specimens were used, and
the data showed that miR-339-5p expression in benign
breast tissues was at high levels, with a positive signal
predominantly in luminal epithelial cells in both ductual
and lobular structures, whereas its expression in breast
cancer tissues was lower (P = 0.017, Fig. 4 and Table 1).
Futhermore, we associated miR-339-5p expression
with the clinicopathologic data from the breast cancer
patients and found that miR-339-5p expression was
inversely associated with lymph node metastasis
(P = 0.018) and high clinical stages (P = 0.005). How-
ever, there was no association between miR-339-5p
expression and age, tumor size, tumor grade, c-erbB-2
overexpression, or estrogen receptor and progesterone
receptor status (Table 2).
Association of miR-339-5p expression with overall
survival and relapse-free survival
We then performed Kaplan-Meier analyses to determine
whether miR-339-5p expression was associated with
overall survival and relapse-free survival of the breast
cancer patients. Patients whose primary tumors did not
express miR-339-5p (n = 63) had a mean 5-year overall
survival of 53.0 months (54%), whereas patients with
tumors expressing miR-339-5p (n = 27) had a mean
overall survival of 61.0 months (82%). The difference
was statistically significant (P = 0.019, Fig. 5). Similarly,
a statistically significant association of miR-339-5p with
relapse-free survival was also found (P = 0.011).
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Figure 1 Expression of miR-339-5p in breast cancer cells and tissues. A. miRNA microarray and real-time PCR analysis of miR-339-5p
expression. MDA-MB-231 and MCF-7 cells were grown in monolayer for 5 days, and total RNA was extracted from the cells and subjected to
microarray and real-time PCR analyses. B. Real-time PCR analysis of miR-339-5p expression. Fresh tissue samples from breast cancer patients with
or without lymph node metastasis and from patients with benign breast diseases were obtained from the surgery room. Total RNA was
extracted from the tissues and subjected to real-time PCR analysis.
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showed that miR-339-5p expression was an independent
prognostic factor for 5-year survival of patients with
breast cancer (hazard ratio = 0.38; 95% CI: 0.16-0.92;
P = 0.032).
Discussion
In the current study, our data showed that a number
of miRNAs were differentially expressed in these can-
cer cell lines. One of them was miR-339-5p, which had
a downregulated expression in the more aggressive
breast cancer cell lines and tissue samples. Our further
study showed that miR-339-5p could significantly
decrease tumor cell migration and invasion capacity,
which associated with downregulation of BCL-6
expression in breast cancer cells. In ex vivo, miR-339-
5p expression was lower in breast cancer tissues than
in benign breast tissues, which was associated with an
increase in tumor metastasis to lymph nodes and with
high clinical stages, and tumors expressing miR-339-5p
had better overall and relapse-free survival rates com-
pared with those without miR-339-5p expression.
Thus, miR-339-5p expression was an independent
prognostic factor for these patients. The data from the
current study suggest that miR-339-5p may play an
important role in breast cancer development and
Figure 2 Effects of miR-339-5p on breast cancer cells. A. Regulation of breast cancer cell growth by miR-339-5p. MCF-7 cells were grown and
transiently transfected with miR-339-5p antisense oligonucleotide or scrambled sequence oligonucleotide as negative control for 4 days, and cell
viability was analyzed using a kit. The experiments were in triplicate and repeated twice. B. Wound-healing assay. MCF-7 cells were grown and
transiently transfected with miR-339-5p antisense oligonucleotides or scrambled sequence oligonucleotide as negative control for 3 days and
subjected to the wound-healing assay. Magnification: ×100. C. Transwell migration and Matrigel invasion assays. MCF-7 cells were grown and
transiently transfected with miR-339-5p antisense oligonucleotides or scrambled sequence oligonucleotide as negative control for 2 days and
subjected to migration and invasion assays. Representative photographs (upper) and quantification (lower) are shown. Magnification: ×200.
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ther evaluated as a biomarker for predicting patient
survival.
Indeed, recent studies have reported altered expres-
sion of miR-339-5p in several kinds of solid tumors,
including gastric cancer, lung cancer, and cervical
cancer [25-27]. Tie et al. analyzed the global miRNA
expression profile in highly invasive and low-invasive
gastric cancer cells using a miRNA microarray and
found that miR-339-5p was significantly downregulated
in highly invasive gastric cancer cells [25]. These data
are consistent with our current results for breast cancer
cells. However, these former studies did not pursue
further investigation on miR-339-5p.
We therefore further explored the role of miR-339-5p
in breast cancer cell lines. MCF-7, MDA-MB-231, and
MDA-MB-468 cells have very different capacities for
invasive and metastatic potentials in vivo. The differen-
tial expression of miR-339-5p in these cell lines suggests
that miR-339-5p may play a role in regulation of breast
cancer cell migration and invasion. Our current findings
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Figure 3 Regulation of BCL-6 mRNA expression by miR-339-5p
in breast cancer cells. MDA-MB-231 and MCF-7 cells were grown
and transiently transfected with miR-339-5p mimic and miR-339-5p
ASO, respectively and then subjected to RNA extraction and real-
time PCR analysis.
Figure 4 Expression of miR-339-5p in breast tissue specimens. Paraffin blocks from breast cancer or benign tissue specimens were prepared
for making tissue microarrays, and the sections from the latter were hybridized with miR-339-5p probe in situ hybridization. A. Positive
expression of miR-339-5p in a breast fibroadenoma. B. Positive expression of miR-339-5p in an invasive ductal carcinoma without lymph node
metastasis. C. Negative expression of miR-339-5p in an invasive ductal carcinoma with lymph node metastasis. D. Negative control probe in an
invasive ductal carcinoma. Magnification: ×200.
Table 1 Expression of miR-339-5p in cancerous, adjacent
normal and benign breast tissues
miR-339-5p expression
Group n Negative, n (%) Positive, n (%)
Adjacent normal 24 12 (50.0) 12 (50.0)
Benign breast disease 26 11 (42.3) 15 (57.7)
Breast cancer 90 63 (70.0) 27 (30.0)*
Note: * P = 0.017.
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migration and invasion capacity of MDA-MB-231 cells,
whereas knockdown of miR-339-5p expression in
MCF-7 increased migration and invasion of the cells. In
contrast, miR-339-5p showed limited ability to affect
breast cancer cell growth.
In our bioinformatic analyses to search for potential
target genes of miR-339-5p, we focused our attention
on BCL-6, because BCL-6 contains the binding sites of
miR-339-5p in its 3’-UTR. The human proto-oncogene
BCL-6 encodes a BTB/POZ-zinc finger transcriptional
repressor that was originally characterized as a regula-
tor of B-lymphocyte development and growth and has
been implicated in the pathogenesis of B cell lym-
phoma [28,29] and in cancers of many organs, includ-
ing breast cancer [30,22-24]. For example, Bajalica
et al. reported that BCL-6 was expressed in mammary
glands of nonpregnant animals and during early preg-
nancy and that BCL-6 could prevent ductal formation
and apoptosis [30]. BCL-6 was found to be overex-
pressed in breast cancer [22] and in 68% of histological
high-grade ductal breast cancers, clinically the most
aggressive subgroup of breast cancer. BCL-6 was able
to prevent mammary epithelial differentiation [23].
Furthermore, Pinto et al. [24] demonstrated that BCL-
6 could significantly increase expression of three
metastasis-related genes – CXC-chemokine receptor 4
(CXCR4) [31], fms-like tyrosine kinase-1 (FLT-1) [32],
and integrin-b-3 [33] – in breast cancer cell lines. Our
current study revealed that miR-339-5p could inhibit
expression of BCL-6 mRNA, which is associated with
suppression of the migration and invasion of breast
cancer cells. However, it is not clear whether inhibition
of BCL-6 expression by miR-339-5p is direct or indir-
ect; further studies are needed for clarification.
Our current study also found that lost expression of
miR-339-5p was associated with breast cancer metastasis
to lymph nodes, higher clinical stages, poor overall sur-
vival, and poor relapse-free survival of breast cancer
patients. To our knowledge, this is the first study of
miR-339-5p in breast cancer, although a number of
Table 2 Association of miR-339-5p expression with
clinicopathological data from breast cancer patients
Variable n MiR-339-5p expression, n (%) P value
Age (years)
≤35 6 0 (0) 0.12
35-55 48 18 (37.5)
> 55 36 9 (25.0)
Tumor size (cm)
≤2 4 2 (50.0) 0.67
2-5 68 20 (29.4)
> 5 18 5 (27.8)
Lymph node metastases
0 29 14 (48.3) 0.018
1-3 33 9 (27.3)
> 3 28 4 (14.3)
Grade
I 4 1 (25.0) 0.17
II 57 21 (36.8)
III 29 5 (17.2)
Stage 0.005
I - II 50 21 (42.0)
III - IV 40 6 (15.0)
Estrogen receptor
- 57 18 (36.1) 0.67
+ 33 9 (27.3)
Progesterone receptor
- 56 16 (28.6) 0.70
+ 34 11 (32.4)
c-erbB-2 expression
Low 59 18 (30.5) 0.89
High 31 9 (29.0)
P = 0.019
miR-339-5p Negative
miR-339-5p  Positive
P = 0.011
miR-339-5p Negative
miR-339-5p  Positive
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Figure 5 Association of miR-339-5p expression with overall survival and relapse-free survival of the patients with breast cancer. A,
Overall survival (OS). B, Relapse-free survival (RFS).
Wu et al. BMC Cancer 2010, 10:542
http://www.biomedcentral.com/1471-2407/10/542
Page 8 of 10other miRNAs have been reported to be altered in
breast cancer. For example, Scott and colleagues
reported that miR-125a and miR-125b could reduce
invasion and migration capacity of SKBR3 breast cancer
cells through targeting ERBB2 and ERBB3 genes [34].
A recent study by Wu et al. using breast cancer tissues
and cells demonstrated the important role of miR-205
in breast cancer progression. They found that miR-205
was highly expressed in normal breast tissues and non-
malignant breast epithelial cell lines and that ectopic
expression of miR-205 significantly reduced breast can-
cer cell proliferation, invasion, and metastasis in vivo
[35]. In addition, two independent studies [7,36] showed
that expressions of miR-335, miR-206, miR-126, and
miR-146 were significantly decreased in highly invasive
breast cancer cell lines, which is consistent with our
microarray data presented here.
Conclusions
This study suggests that miR-339-5p may play an
important role in breast cancer progression. However,
future study will be needed to verify the usefulness of
miR-339-5p as a biomarker in other populations before
miR-339-5p can be used in the clinic.
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